… antibody, compared to everolimus in 821 patients with kidney cancer pretreated with …
bicalutamide (50 mg/day) was compared in 396 patients with castration-resistant prostate cancer …

… and decreased prostate tumor volume. The first-generation ARAs including bicalutamide, …
In these combination trials, as well as with the use of the mTOR inhibitor everolimus and the …

… progression on an aromatase inhibitor, adding everolimus, an oral mTOR inhibitor to … for
long-acting agents including nilutamide and bicalutamide and a minimum 4-week washout …

… everolimus by decreasing tumor burden in a murine model of PCa. Interestingly, in this study,
MLN0128 and not everolimus … AR inhibitor bicalutamide significantly delayed CRPC tumor …

… as bicalutamide, nilutamide, and flutamide. This approach are often used as an adjunct to
radiotherapy for more aggressive localized prostate cancer and … and everolimus in metastatic …

… evaluating everolimus efficacy in BPH or prostatitis; however, considering that everolimus is
… prostatic inflammation and future studies addressing this hypothesis should be conducted. …

… in prostate cancer patients have been disappointing thus far. Studies of the mTOR inhibitors
rapamycin, everolimus… the androgen receptor antagonist bicalutamide failed to demonstrate …

… Other phase II studies of everolimus, alone or in combination with bicalutamide, bevacizumab,
or chemotherapy, as well as trials testing other mTOR inhibitors such as temsirolimus and …

… However, at the end of 2011, two agents received approval for the treatment of unresectable
pNETs: everolimus and sunitinib. We will describe the data on everolimus and interpret its …

… 1) testing everolimus versus placebo … everolimus and bicalutamide. In the first study, the
combination showed limited activity, but 31 out of 36 patients were pre-treated with bicalutamide …